Aryoseven
  • Seen : 968 View

0
Aryoseven

aryosevenا is a recombinant active coagulation factor and is a macro-protein molecule (glycoprotein) that is produced by recombinant DNA technology and using BHK infant kidney cells. The molecular structure and biological activity are similar to those of the coagulation factor extracted from Plasma is human.
This drug activates the pathway of the coagulation cascade through the bloodstream. In patients with congenital hemophilia A and B who have coagulation factor deficiencies of 8 and 9, they are usually injected with coagulation factors 8 and 9 when bleeding episodes or preventing bleeding during surgery. (Extracted from Plasma Human or recombinant type). A number of these patients begin to develop inhibitors of antibodies over time due to frequent recurrence of these factors.
These inhibitors gradually reach a level that inhibits all intravenous coagulation factors 8 and 9 and prevents their coagulation effect. In this case, the intake of seven coagulation factor in doses is relatively high

Saler Company Information

Company : AryoGen Pharmed
More Information : View
Online order registration form
No comments have been posted yet
loading
Your comment has been sent
Aryoseven

aryosevenا is a recombinant active coagulation factor and is a macro-protein molecule (glycoprotein) that is produced by recombinant DNA technology and using BHK infant kidney cells. The molecular structure and biological activity are similar to those of the coagulation factor extracted from Plasma is human.
This drug activates the pathway of the coagulation cascade through the bloodstream. In patients with congenital hemophilia A and B who have coagulation factor deficiencies of 8 and 9, they are usually injected with coagulation factors 8 and 9 when bleeding episodes or preventing bleeding during surgery. (Extracted from Plasma Human or recombinant type). A number of these patients begin to develop inhibitors of antibodies over time due to frequent recurrence of these factors.
These inhibitors gradually reach a level that inhibits all intravenous coagulation factors 8 and 9 and prevents their coagulation effect. In this case, the intake of seven coagulation factor in doses is relatively high

Saler Company Information

Company : AryoGen Pharmed
More Information : View
Online order registration form